Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial
Open Access
- 8 May 2023
- journal article
- research article
- Published by BMJ in BMJ Paediatrics Open
- Vol. 7 (1), e001913
- https://doi.org/10.1136/bmjpo-2023-001913
Abstract
Introduction Severe sialorrhoea is a common, distressing problem in children/adolescents with neurodisabilities, which has adverse health and social consequences. The SALIVA trial is designed to evaluate the efficacy and safety of a paediatric-specific oral solution of glycopyrronium along with its impact on quality-of-life (QoL), which has been lacking from previous trials of sialorrhoea treatments. Methods and analysis A double-blind, placebo-controlled, randomised phase IV trial is ongoing in several centres across France. Eighty children aged 3–17 years with severe sialorrhoea (≥6 on the modified Teachers Drooling Scale) related to chronic neurological disorders in whom non-pharmacological standard of care has already been implemented or has failed, will be recruited. Patients will be randomised 1:1 to receive a 2 mg/5 mL solution of glycopyrronium bromide (Sialanar 320 µg/mL glycopyrronium) or placebo three times daily during a 3-month blinded period. After Day 84, participants will be invited into a 6-month, open-label study extension period, where they will all receive glycopyrronium. The primary endpoint of the double-blind period will be the change from baseline to Day 84 in the Drooling Impact Scale (DIS), a validated measure to assess sialorrhoea. A series of secondary efficacy endpoints involving change in total DIS, specific DIS items and response (DIS improvement ≥13.6 points) will be analysed in a prespecified hierarchy. QoL data will be collected from parents, caregivers and patients where possible using specific DIS questions and DISABKIDS questionnaires. Safety endpoints, including adverse events, will be assessed throughout the trial periods. Ethics and dissemination In total, 87 children have been recruited and recruitment is now complete. Final results are expected by the end of 2023. Findings will be presented at conferences and published in peer-reviewed journals. Trial registration number EudraCT 2020-005534-15.Funding Information
- Proveca Ltd (No award/grant number)
This publication has 16 references indexed in Scilit:
- The association of drooling and health-related quality of life in children with cerebral palsyNeuropsychiatric Disease and Treatment, 2012
- Prevalence and predictors of drooling in 7‐ to 14‐year‐old children with cerebral palsy: a population studyDevelopmental Medicine and Child Neurology, 2012
- Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in childrenNeuropsychiatric Disease and Treatment, 2011
- Management of drooling in childrenArchives of Disease in Childhood: Education & Practice, 2010
- The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilitiesDevelopmental Medicine and Child Neurology, 2010
- Drooling in cerebral palsy: hypersalivation or dysfunctional oral motor control?Developmental Medicine and Child Neurology, 2009
- Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and careDevelopmental Medicine and Child Neurology, 2006
- The European DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescentsHealth and Quality of Life Outcomes, 2005
- Social interaction and self-esteem of children with cerebral palsy after treatment for severe droolingEuropean Journal of Pediatrics, 2005
- Treatment of Sialorrhea With GlycopyrrolateArchives of Pediatrics & Adolescent Medicine, 2000